Aethlon Medical (NASDAQ:AEMD – Get Free Report) released its quarterly earnings results on Wednesday. The medical equipment provider reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.09, Zacks reports.
Aethlon Medical Stock Performance
Shares of NASDAQ AEMD opened at $0.63 on Friday. Aethlon Medical has a fifty-two week low of $0.24 and a fifty-two week high of $1.85. The company has a market cap of $8.81 million, a PE ratio of -0.22 and a beta of 1.88. The business has a 50-day simple moving average of $0.63 and a two-hundred day simple moving average of $0.48.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on AEMD. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Aethlon Medical in a research report on Thursday, January 30th. StockNews.com assumed coverage on Aethlon Medical in a research report on Monday, January 27th. They set a “sell” rating on the stock.
About Aethlon Medical
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Further Reading
- Five stocks we like better than Aethlon Medical
- 3 Dividend Kings To Consider
- Datadog Is in the Doghouse, But This Dip Spells Opportunity
- Ride Out The Recession With These Dividend Kings
- Vertiv Stock Under Pressure: Is Opportunity Knocking?
- Upcoming IPO Stock Lockup Period, Explained
- MicroStrategy’s 8% Preferred Stock: What Investors Should Know
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
